Upharmacia February 2017
parties and to implement their
alienation within the property
complexes or separately”.
In 2016, Arterium climbed to
second position on retail drug
market of Ukraine increasing
its market share form 3.76% in
2015 to 4.44%. The Corporation
includes the producer of herbal
preparations Galychpharm and
the manufacturer of antibiotics
Kyivmedpreparat. The
company’s portfolio includes
140 drugs. The main export
market of the company are 11
CIS countries and Vietnam.
Y uria -P harm
L aunched
A nti -A sthma
D rug
Ukrainian producer of phar-
maceuticals Yuria-Pharm
expanded its respiratory
portfolio by launching Derkast®
(theophylline, combinations
excl. psycholeptics) intravenous
solution. The drug is indicated
for the treatment of patients
with moderately to severely
bronchial asthma (BA)
exacerbation and chronic
obstructive pulmonary disease
(COPD).
Yuria-Pharm is a leading
producer of intravenous
medications in Ukraine. In 2016,
the company maintained 13th
position on Ukrainian retail drug
market by sales in values. It has
become the second company on
the hospital drug market with
market share of over 7.2%.
S hire J oined
APR a D
Shire Ukraine has become
www.upharma-c.com
a member of The Ukrainian
Association of Pharmaceutical
Research & Development
(APRaD). APRaD unites 15
leading pharmaceutical
companies, which are
committed to the research
and development, quality
manufacturing and distribution
of innovative medicines.
APRaD gives much emphasis
to co-operation with Ukrainian
authorities, and other
international organizations
concerned with health and
pharmaceutical industry-
related issues. The Association
is a member of the European
Federation of Pharmaceutical
Industries and Associations –
EFPIA.
to more than 15 countries.
In Jun 2016, Irish company
Shire finished the merger with
Baxalta Inc. worth USD 32 bn.
The new company has become
the global market leader in rare
diseases and other specialized
disorders.
B iofarma to
E xport F ood
S upplement in S lovakia
Food supplements Subalin,
Subalin-Forte and Biosporin-
Forte of Ukrainian company
Biofarma has passed the
quality control by the European
laboratory and have been
registered in Slovakia. The
company is planning to expand
the sales market in the EU in the
near future.
Biofarma producers more than
130 items of medical products in
11 pharmacological groups, but
its main focus is drugs made
of donated human blood. The
company exports its products
7